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Abstract
Background: EGF receptor variant III (EGFRvIII) is the most common variant of the EGF receptor observed in
human tumors. It results from the in frame deletion of exons 2-7 and the generation of a novel glycine residue at
the junction of exons 1 and 8. This novel juxtaposition of amino acids within the extra-cellular domain of the EGF
receptor creates a tumor specific and immunogenic epitope. EGFRvIII expression has been seen in many tumor
types including glioblastoma multiforme (GBM), breast adenocarcinoma, non-small cell lung carcinoma, ovarian
adenocarcinoma and prostate cancer, but has been rarely observed in normal tissue. Because this variant is tumor
specific and highly immunogenic, it can be used for both a diagnostic marker as well as a target for
immunotherapy. Unfortunately many of the monoclonal and polyclonal antibodies directed against EGFRvIII have
cross reactivity to wild type EGFR or other non-specific proteins. Furthermore, a monoclonal antibody to EGFRvIII is
not readily available to the scientific community.
Results: In this study, we have developed a recombinant antibody that is specific for EGFRvIII, has little cross
reactivity for the wild type receptor, and which can be easily produced. We initially designed a recombinant
antibody with two anti-EGFRvIII single chain Fv’s linked together and a human IgG1 Fc component. To enhance
the specificity of this antibody for EGFRvIII, we mutated tyrosine H59 of the CDRH2 domain and tyrosine H105 of
the CDRH3 domain to phenylalanine for both the anti-EGFRvIII sequence inserts. This mutated recombinant
antibody, called RAb
DMvIII, specifically detects EGFRvIII expression in EGFRvIII expressing cell lines as well as in
EGFRvIII expressing GBM primary tissue by western blot, immunohistochemistry (IHC) and immunofluorescence (IF)
and FACS analysis. It does not recognize wild type EGFR in any of these assays. The affinity of this antibody for
EGFRvIII peptide is 1.7 × 10
7 M
-1 as determined by enzyme-linked immunosorbent assay (ELISA).
Conclusion: This recombinant antibody thus holds great potential to be used as a research reagent and diagnostic
tool in research laboratories and clinics because of its high quality, easy viability and unique versatility. This
antibody is also a strong candidate to be investigated for further in vivo therapeutic studies.
Background
According to Global Health Council despite advances in
the understanding of cancer biology, malignant neo-
plasms remain the second leading cause of mortality in
United States. Novel therapies are needed and over the
past two decades new immunotherapy strategies have
emerged as a promising approach. The success of these
immunotherapeutic strategies is highly dependent on
finding an ideal antigen to target. One such target is the
EGF receptor which is over or aberrantly expressed in a
variety of human cancers [1-12]. However, the fact that
the EGF receptor is present on normal tissue could lead
to possible deleterious side effects or immune tolerance
when treating patients with reagents solely targeting the
EGF receptor. A tumor specific antigen would be more
ideal. Epidermal growth factor receptor variant III
(EGFRvIII) is the most common variant of the EGF
receptor and is expressed in a number of solid tumors
including glioblastoma multiforme (GBM), breast adeno-
carcinoma, medulloblastoma and ovarian adenocarci-
noma, but has only rarely been observed in normal
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any medium, provided the original work is properly cited.tissue [13-15]. This variant receptor results from an in-
frame deletion of exons 2-7 of the wild type EGF recep-
tor. This causes a deletion of a large portion of the
extracellular domain and the generation of a novel gly-
cine at the fusion junction between exon 1 and exon 8
[16-18]. EGFRvIII is ligand independent yet constitu-
tively active and when expressed in cells it leads to
unregulated growth, survival, invasion, and angiogenesis
[19]. EGFRvIII is an ideal target for immunotherapy
because the juxtaposition of exon 1 and 8 sequences
p l u st h en o v e lg l y c i n ec r e a t e sah i g h l yi m m u n o g e n i c
tumor specific antigen, and the receptor itself leads to a
cancer phenotype due to its constitutive activity
[1,20-22].
There are a number of immune approaches that speci-
fically target EGFRvIII. For example, a peptide vaccine
targeting this mutant receptor is currently being tested
in clinical trials for GBM patients [23,24]. Another
approach is the development of antibodies that recog-
nize EGFRvIII which can be used for diagnostic/labora-
tory purposes or for therapeutic purposes either alone
or attached to a cytotoxic or radiolabeled adjunct
[25,26]. Many of the monoclonal antibodies that target
EGFRvIII, however, have cross reactivity with the wild
type EGF receptor or other non-specific proteins [27] or
comparatively have low affinity. While polyclonal anti-
bodies are apparently highly sensitive and of high affi-
nity, it is difficult to produce them in mass quantities.
An additional complicating factor is that the rights to
the antibody for EGFRvIII are patented and have not
been made widely available for either scientific or medi-
cal use.
To generate a highly specific and cost effective antibody
that could be used for scientific and clinical purposes, we
developed a recombinant antibody. Recombinant anti-
body technology has gained popularity in recent years
because of its many advantages when compared with the
production of monoclonal or polyclonal antibodies. First,
no animals are needed and the manufacturing time is
relatively short compared with conventional methods.
Moreover, the quality and quantity of the final product is
superior when compared to conventional antibody pro-
duction. Recombinant antibodies are formed by combin-
ing single-chain Fv antibodies, consisting of VH and VL
chains, by a flexible linker [28]. In this report, we
describe how we created a recombinant antibody that
specifically recognizes EGFRvIII and demonstrate its spe-
cificity by western blot analysis, immunohistochemistry
(IHC), immunofluorescence (IF), enzyme-linked immuno-
sorbent assay (ELISA) and flow cytometry analysis
(FACS). This easily produced and highly specific recom-
binant antibody holds great potential to be used as a
diagnostic and a therapeutic tool.
Results
Western Analysis
We constructed the first recombinant EGFRvIII antibody,
RAb
vIII, using the sequence of MR1-1, an scFv developed
against EGFRvIII (Figure 1) [29]. To determine the speci-
ficity of RAb
vIII antibody for EGFRvIII, we used it for
western blot analysis. Consistent with previously pub-
lished data, the RAb
vIII antibody recognizes the 145 kDa
EGFRvIII protein band in U87-vIII cells stably expressing
EGFRvIII (U87-vIII) compared to the U87-MG untrans-
fected cells (Figure 2A) [30]. The RAb
vIII antibody also
faintly recognized the endogenous 170 kDa wild type
EGF receptor and it strongly recognize a 45 kDa protein
band in both U87-vIII and U87-MG control cells. We
speculated that the 45 kDa protein was cross-reaction
with another EGF receptor variant that we have recently
identified, called mLEEK. MiniLEEK (mLEEK) is the
result of the fusion of exon 1 to exon 23 and is predicted
to be 45 kDa in size (Piccione et al., submitted). This also
creates a glycine at the junction and the fusion junction
(LEEKKGVTVWEL) bears some resemblance to the
EGFRvIII sequence.
The crystal structure of MR1-1 in complex with the
EGFRvIII peptide has been done by Landry et al. [31]
This shows the valine at P9 position of the EGFRvIII
peptide forms a hydrogen bond with tyrosine at H59
and H105 on MR1-1. The mLEEK peptide has a valine
at the identical position. Since RAb
vIII potentially cross
reacted with mLEEK, to eliminate the non-specific 45
kDa band we mutated the tyrosines at H59 and H105 to
phenylalanine.
To determine if the mutated RAb
DMvIII has improved
specificity towards EGFRvIII, we conducted another wes-
tern analysis. We found that RAb
DMvIII now specifically
recognizes only the EGFRvIII 145 kDa protein band and
not the EGFR variant 45 kDa band (Figure 2A). We also
more rigorously tested cross-reaction with wt EGF recep-
tor by performing Western blots using lysates from A431
cells, which express 1 × 10
6 receptors per cell. When we
studied the specificity of RAb
DMvIII towards the overex-
pressed wild type EGFR present in A431 cells we discov-
ered that the RAb
DMvIII antibody did cross-react with the
170 kDa wild type protein (Figure 2B).
Consequently, to further study the specificity of the
RAb
DMvIII under these conditions we expanded our ana-
lysis to include HC2 cells which expresses EGFRvIII at a
level comparable to that of EGFR expressed by A431
(Figure 2B). Western analysis using anti-EGFR antibody
E3138 from Sigma shows that there are similar amounts
of wild type EGFR and EGFRvIII protein expressed in
A431 and HC2 cells (Figure 2B).
Based on the study done by Johns et al. which showed
that monoclonal antibody 806 recognizes overexpressed
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further analyzed both HC2 and A431 cell lysates under
non-reducing western conditions [32]. Western analysis
under these conditions shows that recombinant RAb
DMvIII
recognizes only the EGFRvIII 145 kDa band and not the
wild type EGFR 170 kDa band (Figure 2C) suggesting that
under reducing conditions the EGFR epitope is somewhat
more exposed and accessible to RAb
DMvIII [32]. On the
other hand, the non mutated RAb
vIII consistently recog-
nizes the 170 kDa wild type EGFR band even under non-
reducing western conditions clearly illustrating that
RAb
DMvIII i sam o r es p e c i f i cE G F R v I I Ia n t i b o d yt h a n
RAb
vIII.
Antibody Affinity
To determine the affinity constant of the antibody, we
used the method described by Friguet et al. (1984) [33].
It is necessary that the concentration of the antibody
used in the ELISA should be equal to or less than the
value of dissociation constant of the antibody. Thus a
preliminary ELISA was performed to deduce the disso-
ciation constant of the antibody. From the preliminary
ELISA, the dissociation constant of RAb
vIII and RAb
DM-
vIII is calculated to be approximately 1.7 μMa n d8 8 6
nM, respectively, against EGFRvIII peptide (Figure 3A).
This result suggests that RAb
DMvIII did not lose its affi-
nity after mutation as RAb
DMvIII has a lower dissociation
constant than RAb
vIII.
The indirect ELISA was performed with RAb
DMvIII
using a concentration of 117 nM, which is lower than
its dissociation constant value of 886 nM. The OD
values from this ELISA were placed in a Scatchard plot
equation where the fraction of bound antibody sites a
(determined from the OD values) is plotted on the X
axis and the ratio of the fraction of bound antibody sites
a to free antigen sites c, (a/ c )i sp l o t t e do nt h eYa x i s .
The slope gives the value of -K, the affinity constant of
the antibody, which is 1.7 × 10
7 M
-1 (Figure 3B).
Immunoprecipitation
Immunoprecipitation of HC2 and A431 cell lysates was
performed using RAb
DMvIII and G100 an anti-EGFRvIII
monoclonal antibody (no longer commercially available).
As a negative recombinant antibody control for EGFR
wt and EGFRvIII, we also used RAb
CD133, which utilizes
t h es a m ee x p r e s s i o nv e c t o ra sR A b
DMvIII but is directed
against CD133 and recognizes neither EGFR wt nor
EGFRvIII. HC2 cell lysates immunoprecipitated with
RAb
DMvIII and G100 antibody and then further immu-
noblotted with E3138 antibody showed the expected 145
kDa band corresponding to EGFRvIII in the pellet
whereas RAb
CD133 did not show the 145 kDa band in
the pellet as it does not bind to EGFRvIII (Figure 4A)
On the contrary, when A431 cell lysates were immuno-
precipitated with either RAb
DMvIII, G100 or RAb
CD133
and then immunoblotted with the E3138 antibody,
the170 kDa bands corresponding to wt EGFR was found
in the supernatant (Figure 4B). This suggested that even
when abundant amounts of wt EGFR protein is present
RAb
DMvIII did not bind to any wild type EGFR.
Immunofluorescence
Since the specificity of RAb
DMvIII is greatly enhanced
under native conditions, we decided to test the recombi-
nant antibody specificity under in vivo conditions. To
this end, indirect immunofluorescence was performed on
HC2 and A431 cells with RAb
DMvIII at a concentration of
0.25 μg/μl. Images were taken using a Leica SP2 AOBS
confocal microscope. Consistent with previous findings,
the RAb
DMvIII shows that the EGFRvIII protein is both
membrane bound and has an intracellular localization
(Figure 5A) [1,6,34]. To verify the specificity of the
RAb
DMvIII antibody we conducted a peptide competition
using the EGFRvIII epitope (LEEKKGNYVVTDHC). The
presence of the EGFRvIII epitope completely blocked
RAb
DMvIII from interacting with the EGFRvIII found in
the HC2 cells (Figure 5C), as compared to the scramble
Figure 1 Schematic of the RAb
DMvIII antibody. The genes for the anti-EGFRvIII scFvs were cloned into the pBudCE4.1 dicistronic vector. The Ig
k-chain signal sequence at the 5’ end of each sequence allowed the secretion of the molecule in the culture media. “Knobs-into-holes”
configuration and the two cysteine residues at the 3’ end of each CH3 domain stabilize the construct. Sequence corresponding to a V5 epitope
was cloned at the 3’ end of one anti-EGFR scFvs and the other anti-EGFR scFv has Myc as well as a 6xHis tag at 3’end.
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EGFRvIII (Figure 5B). Additionally, the A431 cells that
over express wild type EGFR did not demonstrate any
signal with RAb
DMvIII (Figure 5D), whereas the anti-
EGFR antibody recognizes a strong EGFR wild type sig-
nal demonstrating that the A431cells retain high expres-
sion of the wild type protein (Figure 5E). Together these
findings indicate again that this recombinant antibody is
highly specific towards EGFRvIII.
Immunohistochemistry
Immunohistochemistry (IHC) is another sensitive bio-
chemical test to monitor for the expression of EGFRvIII.
To determine if the RAb
DMvIII antibody could be used
for IHC, we used mouse tumor xenografts from HC2
and A431 cells (Figure 6A-C) and GBM cases (Figure
6D-G). The tumor xenografts contain both HC2 tissue
(top) and A431 tissue (bottom). RAb
DMvIII shows strong
positivity to the HC2 section which is comparable in
intensity to slides stained with the positive control anti-
EGFRvIII polyclonal antibody (Figure 6A &6B). In addi-
tion, the RAb
DMvIII antibody did not stain the A431
tissue sections (Figure 6A). The recombinant antibody
RAb
CD133 was used as a negative antibody control (Fig-
ure 6C). We extended our findings to two GBM cases,
one positive for EGFRvIII (08023) and one negative (04-
34497). Consistent with the mouse tumor xenografts,
the RAb
DMvIII antibody only stained the GBM positive
for EGFRvIII and had no cross reactivity to the negative
GBM case (Figure 6D &6F). As a control, we also
stained these sections with affinity purified polyclonal
anti-EGFRvIII and observed similar results (Figure 6E
and 6G).
Flow cytometry
Because RAb
DMvIII efficiently detects surface EGFRvIII,
we asked if it might be an effective reagent for flow
cytometry experiments. Under native conditions we
o b s e r v e dt h a tR A b
DMvIII binds to surface expressed
EGFRvIII very efficiently. Figure 7A shows an overlay of
plots from HC2 cells stained with increasing concentra-
tion of RAb
DMvIII (0.1 μg, 1 μga n d2μgp e r1 0
6 cells).
The dot blot and histogram in blue represents human-
IgG1 isotype control and as low as 0.1 ug of RAb
DMvIII
shows a significant shift in fluorescence intensity. Higher
concentration of RAb
DMvIII (1 μga n d2μg) show the
presence of multiple peaks consistent with the immuno-
fluorescence assay (Figure 5) which shows different
levels of EGFRvIII expression. To look at the sensitivity
of RAb
DMvIII in identifying and isolating EGFRvIII
expressing cells, we mixed NIH3T3 and HC2 cells at a
1:1 stoichiometry prior to staining with RAb
DMvIII.
RAb
DMvIII was able to clearly identify and separate the
HC2 cells from NIH3T3 cells.
Figure 2 Western Blot analysis of RAb
DMvIII antibody.A )3 0u g
of U87vIII and U87 wild type cell lysate loaded under reducing
conditions on 4-20% SDS-PAGE. A) RAb
vIII recognizes 145 kDa band
which corresponds to the EGFRvIII and 45 kDa unspecific protein
band. A) RAb
DMvIII recognizes only 145 kDa protein band. B)
RAb
DMvIII recognizes 170 KDa protein band in 30 ug of A431 cell
lysate (cells overexpressing EGFR) and 145 kDa band in 30 ug of
HC2 cell lysate under reducing conditions. B) EGFR antibody
recognizes equal amount of protein in both HC2 and A431 cell
lysate under reducing conditions. C) RAb
DMvIII under non reducing
conditions detect only 145 kDa protein band whereas RAb
vIII still
recognizes 145 kDa and 170 kDa protein bands in non reducing
conditions. C) Actin antibody under reducing condition shows equal
amount of protein loaded in the wells.
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DMvIII by Saturation ELISA. Calibration curve of the binding of RAb
DMvIII and RAb
vIII recombinant
antibodies to coated EGFRvIII in the ELISA. A) The concentration range for RAb
DMvIII and RAb
vIII was 20 to 0.02 ug/ml (x axis) and the
absorbance was read at 450 nm (Y axis). The assay was analyzed twice. B) Saturation ELISA shows the Scatchard plot of the binding of RAb
DMvIII
to EGFRvIII. The resulting data is plotted as ratio of a/c (y axis) as function of alpha (x axis) where a is the fraction of bound antibody sites and c
is the concentration of free antigen. The slope is -K which is the affinity constant of antibody and that is 1.7 × 10
7 liters/mole (M
-1).
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binant EGFRvIII antibodies was the potential cross-reac-
tivity towards wt EGFR under conditions where the
receptor is over-expressed such as that in A431 cells.
Flow cytometry allows quantitation of any potential
cross-reaction under native conditions. Figure 7C is the
overlap of plots of A431 (black) and HC2 (blue) cells
with RAb
DMvIII. There is very little reactivity of RAb
DM-
vIII with A431 as compared to HC2 cells demonstrating
that this reagent does not cross-react with wt EGFR.
We further tested RAb
DMvIII for surface staining of
freshly primary tumor cells and observed about 14% of
cells to be EGFRvIII positive over the isotype control.
Discussion
In this work, we have constructed a novel recombinant
antibody, RAb
DMvIII, which specifically recognizes
EGFRvIII. Based upon a previously described scFv
against EGFRvIII, we have performed further mutagen-
esis to eliminate cross reaction with a 50 kDa band. We
have demonstrated the specificity of this antibody for
EGFRvIII and not wt EGFR or any other protein by sev-
eral methods. Unlike other monoclonal anti-EGFRvIII
antibodies, this antibody is broadly useful because it
recognizes the EGFRvIII epitope in several assays
including ELISA, IF, IHC, western blot analysis, and
flow cytometry.
A distinct advantage is that recombinantly produced
antibodies require no animal for production but other-
wise have the properties of conventional antibodies but
with additional, improved properties. Indeed, the
RAb
DMvIII has been engineered to have an IgG Fc
region, which confers long serum half life, and has
selected to support secondary immune functions, such
as antibody dependent cellular cytotoxicity (ADCC) and
complement mediated cytotoxicity (CMC) [35,36]. Stu-
dies have demonstrated that Fc-containing BsAb and
other fusion proteins do retain the full effector mechan-
isms of the Fc component [36,37].
Effective tumor targeting requires that the antibody
should have an affinity for its tumor antigen but extremely
high affinity may in fact be detrimental [38]. Previous stu-
dies have shown that very high affinity interactions of 10
9
M
-1 between antibodies and tumor antigens may actually
impair efficient tumor penetration of the monoclonal anti-
bodies and thus diminish effective in vivo targeting [39].
Fujimori et al. [40] and Van Osdol et al. [41] have also
demonstrated that higher affinity monoclonal antibodies
do not homogenously distribute and show less killing of
the target cancer cells. According to Robinson et al., a
high antibody affinity restricts the localization and tumor
penetration of Fv antibody molecules [42]. In another
study, Langmuir et al. [26] have shown that a lower affinity
mAb of 5.2 × 10
7 M
-1 was nearly as toxic as a mAb with
an affinity of 1.9 × 10
9 M
-1. Our antibody has an affinity of
1.7 × 10
7 M
-1 as shown by saturation ELISA so it could be
a reasonable candidate for therapeutic studies.
In separate studies, we have already begun to explore
the effectiveness of the RAb
DMvIII in targeting tumor
spheres derived from glioblastoma tumors. These
experiments have already shown that this reagent speci-
fically lyse the cells expressing EGFRvIII and spare nor-
mal neural stem cells (Mitra et al., submitted). We
performed cytotoxicity assays using a coupled lumines-
cence method on various EGFRvIII transfected cell lines
with human NK cells as effectors and found that this
reagent significantly induces cell killing of EGFRvIII
transfected cells. RAb
DMvIII also remarkably reduces the
sphere initiating frequency on GBM cells but not in
normal cells as it has been shown that EGFRvIII is
required for the maintenance of glioma growth in vivo
[43]. To further investigate this reagent in mouse mod-
els, two GBM sphere lines were incubated with either
RAb
DMvIII,R A b
CD133 or a non-specific human control
Figure 4 Immunoprecipitation of EGFRvIII by RAb
DMvIII.
Immunoprecipitation was performed with RAb
DMvIII, Monoclonal
EGFRvIII antibody and RAb
CD133 (negative control for our
recombinant antibody) on HC2 and A431 cell lysates. A) HC2 lysates
immunoprecipitated by Monoclonal EGFRvIII antibody, RAb
DMvIII
showed 145 kda band corresponding to EGFRvIII in the pellet
whereas 145 kda band is seen in the sup of RAb
CD133 when
immunoblotted with E3138 antibody from sigma. B) On the other
hand A431 cell lysate showed 170 kda protein band corresponding
to EGFR in the supernatant of Monoclonal EGFRvIII antibody,
RAb
DMvII1 and RAb
CD133samples.
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Page 6 of 13antibody and orthotopically injected into the cortex of
NOD-SCID mice. Tumor formation was analyzed after
26 weeks which revealed a higher incidence of human
tumor cells engraftment with RAb
CD133 and Hu-IgG1 as
compared to RAb
DMvIII (Mitra et al., submitted). In
order to provide this reagent to other researchers and
for future studies, we are planning to scale up antibody
production using hollow fiber bioreactor system. Hence
this antibody could be of great significance in the field
of brain tumor research.
Conclusion
Despite significant advances in the field of neuro-oncol-
ogy and immunology, there is no widely available
Figure 5 Detection of specificity of RAb
DMvIII by Immunofluorescence. A) Immunofluorescence study shows that RAb
DMvIII detects EGFRvIII
protein in HC2 cells, B) Scrambled peptide competition shows detection of the EGFRvIII signal in HC2 cells by RAb
DMvIII, C) Specific peptide
(EGFRvIII) competition dampens the signal in HC2 cells, D) No signal is detected in A431 cells by RAb
DMvIII, E) EGFR signal is detected in A431
cells by anti-EGFR antibody (sc-130, Santa Cruz).
Figure 6 Detection of EGFRvIII by RAb
DMvIII Immunohistochemistry. (A-C) Immunohistochemical staining of U87vIII & A431 mouse tumor
xenografts and (D-G) Glioblastoma section. A) Staining of A431 and U87vIII with polyclonal EGFRvIII antibody. B) RAb
DMvIII antibody staining, C)
RAb
CD133antibody staining. D) Glioblastoma 08-023 staining with RAb
DMvIII. E) Glioblastoma 08-023 staining with polyclonal EGFRvIII ab. F)
Glioblastoma 04-34497 stained with polyclonal EGFRvIII antibody and G) RAb
DMvIII staining of 04-34497.
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DMvII1 by Flow cytometry. Flow cytometric analysis of surface expressed EGFRvIII. A) 1 × 10
6 cells HC2 cells were
stained with increasing concentration of RAb
DMvIII: 0.1 μg (purple), 1 μg (red) and 2 μg (green). The dot blot (left panel) and histogram in blue
represents human-IgG1 isotype control. B) NIH3T3 and HC2 cells were mixed in a 1:1 ratio prior to staining with RAb
DMvIII revealing distinct
identification of an EGFRvIII cell population. C) Overlay of flow cytometric plots of A431 (black) cells and HC2 cells (blue) stained with RAb
DMvIII,
showing clear selectivity for EGFRvIII expression over EGFR expression. D) Freshly dissociated human GBM tumor stained with RAb
DMvIII shows
the presence of surface EGFRvIII on 13% of cells (right panel). The dot blot (left panel) represents human-IgG1 isotype control.
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more, there is no EGFRvIII antibody clinically proven to
be used on patients because of cross reactions and other
high risk allergic reactions due to murine Fc portion of
the monoclonal antibodies. RAb
DMvIII has shown high
specificity towards EGFRvIII and thus holds great poten-
tial to be further investigated for therapeutic purposes.
Methods
Cell Culture
U87-MG, HEK293, A431, and HC2 cell lines were
obtained from the American Type Culture Collection
(ATCC). U87-MGvIII, a human glioma cell line stably
transfected with EGFRvIII, was generously donated by
Dr Donald O’Rourke. Cell lines were grown in Dulbec-
co’s modified Eagle’sm e d i u m( D M E M )( g l u c o s ea t4 . 5
g/L) supplemented with either 10% fetal bovine serum
or calf serum as per cell line requirement, 100 units/ml
penicillin, 100 μg/ml streptomycin, and 100 μg/ml kana-
mycin sulfate. The U87-MGvIII cell lines were main-
tained in Geneticin (G418) selection at 500 μg/mL.
Tumor Sections for Immunohistochemistry
NOD-SCID mice were injected subcutaneously with
either 1 × 10
6 U87-MGvIII or A431 cells in the right
hind flank of athymic mice. After fourteen days, the
mice were sacrificed and the flank tumors were dis-
sected out and fixed in 10% formalin. Four micron tis-
sue sections of both A431 and U87-MGvIII tumors
were cut and mounted on the same slide. Cut and
mounted primary human glioblastoma tumor sections
were obtained from Stanford University brain bank
under IRB approved protocols.
Plasmid Construction and Cloning
The pBudCE4:Her2/neu:CD16 bispecific minibody was a
kind gift from Dr. Louis Weiner [44]. This construct has
an IgG1 CH3 constant domain linked to one single chain
variable fragment (scFv) against Her2/neu and one scFv
against CD16 in a di-body format on the pBudCE4 vector
backbone. The Her2/neu and CD16 variable fragments
were replaced with MR1-1 [21] as described below. MR1-
1 is a scFv against EGFRvIII selected from a phage dis-
play library which was derived from MR1 (scFv), an anti-
body Fv fragment that recognizes an epitope within the
EGFRvIII-specific sequence. The MR1-1 scFv was artifi-
cially synthesized based on sequence available from Gen-
bank (accession no. U76382).
The plasmid construct pBudCE4:Her2/neu: CD16 was
digested with Not I and Bgl II to remove the Her2/neu
scFv. The artificially synthesized MR1-1 was amplified
using primers AAGGAAAAAAGCGGCCGCACCAT
GGAGACAGACACACTCCTGCTATGGGTACTGCT
GCTCTGGGTTCCA
GGTTCCACTGGTGGTGACGACTACAAGGAC-
GACGATGACAAGCAGGTGAAACTGCAGCAGTCT
(scFvEGFRvIII-Not1-ATG/Igk (F)) and GGAAGATC-
TACCGCCACTGCCACCTCCGCCTGAACCGCCTC-
CACCACTCGAGCCACCTTTGATTTCCAGCTTGG
TGC (scFvEGFRvIII-Linker/BglII(R)) and ligated into
the scFv Her2/neu position. The resulting recombinant
antibody was then digested with Sfil and Xba1 to
remove the scFv for CD16. Primers ACATTGGTGCC-
GAAACCTATTCACTGCTTACTCGCGGCCCAGCC
GGCCCAGGTGAAACTGCAGCAGTCT (scFvLEEK-
Sfil(F)) and GCTCTAGAAC CGCCACTGCCACCTCC
GCCTGAACCGCCTCCACCACTCGAGCCACCTTT-
GATTTCCAGCTTGGTGC (scFvLEEK-XbI/linker(R))
were used to amplify the second EGFRvIII scFv and
ligated into the scFv CD16 position. The plasmid
pBudCE4(scfvEGFRvIII) has the CH3 gene with “knobs-
into-holes” configuration [45]. Additionally the V5
epitope and His6 tag sequences are cloned at the 3’-end
of one anti-EGFRvIII binding arm, whereas the MYC
epitope and His6 tag sequences were cloned at the
3’-end of another anti-EGFRvIII binding arm (Figure 1).
A construct with two scFvs against CD133 was created
in a similar fashion as a control.
Site Directed Mutagenesis
Site directed mutagenesis was used to change tyrosine
H 5 9o ft h eC D R H 2d o m a i na n dt y r o s i n eH 1 0 5o ft h e
CDRH3 domain to phenylalanine for both the anti
EGFRvIII scFv sequence inserts (200519-5, Stratagene).
Primer CTATTCTCCTTACTCTTTTGCTATGGAC-
TACTGGG (F) and primer CCCAGTAGTCCATAG-
CAAAAGAGTAAGGAGAATAG (R) were used
for the H105 mutation while primer ACTGGCGGT-
TATAATACCTTCTATTCAGACAATGTAAAG (F)
and primer CTTTACATTGTCTGAATAGAAG-
GTATTATAACC GCCAGT (R) were used for the
H59 mutation. The resulting mutated vector is called
pBudCE4(DMscfvEGFRvIII) and the antibody produced
by this construct is called RAb
DMvIII whereas the anti-
b o d yp r o d u c e db yp B u d C E 4 ( s c f v E G F R v I I I )a n d
pBudCE4(scfvCD133) are called RAb
vIII and RAb
CD133
respectively.
Transfection, Collection and Purification of Antibody
The pBudCE4scfvEGFRvIII, pBudCE4scfvCD133 and
pBudCE4DMscfvEGFRvIII plasmids were stably trans-
fected into HEK293 cells using calcium phosphate, and
the positive clones were selected using zeocin at 400 μg/
ml. Media was collected from the stably transfected cells
and the His-tagged antibodies were isolated and purified
using Ni-NTA agarose (R901-15, Invitrogen) according
to the manufacturer’s recommended protocol. The anti-
bodies were eluted using 500 mM imidazole. The
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Page 9 of 13fractions containing the antibodies were identified
through Coomassie staining of SDS PAGE. The fractions
containing the antibody protein were combined and dia-
lyzed against phosphate buffer solution (PBS). The pro-
tein concentration was determined by a Bio-Rad Dc
protein assay.
Western Blot Analysis
Confluent HC2 and A431 cells were washed with ice-
cold PBS and lysed using a buffer containing 10 mM
Na2HPO4, 150 mM NaCl, 1% Triton X-100, 0.5%
sodium deoxycholate, 0.1% sodium dodecyl sulfate, 0.2%
sodium azide, 0.004% sodium fluoride, 1 mM NaVO4,
25 mM b-glycerophosphoric acid, 100 μgo fp h e n y l -
methanesulfonyl fluoride/ml, 10 μg of aprotinin/ml, and
10 μg of leupeptin/ml (pH 7.35). Cell lysates were cen-
trifuged at 12,000 × g for 10 min at 4°C to clear out cell
debris, and protein concentration was determined by
Bio-Rad DC protein assay. For gel electrophoresis under
non-reducing conditions, forty micrograms of cell lysate
was prepared in 6x Laemmli Sample Buffer lacking b-
mercaptoethanol and the samples were not boiled. The
proteins were resolved on 4-20% Tris-glycine SDS-
PAGE gels (Invitrogen) and transferred to nitrocellulose
membrane for immunoblot analysis. The membranes
were blocked with blocking buffer 5% Blotto (100 mM
Tris [pH 7.5], 0.9% NaCl, 0.1% Tween 20 with 5% non-
fat dry milk) and incubated with the following antibo-
dies: RAb
vIII,R A b
DMvIII, mouse anti-actin (MAB1501R,
Chemicon), and mouse anti-EGFR (E3138, Sigma
Aldrich). Horse radish peroxidase (HRP) affinity pure
Donkey anti-Human IgG (709-035-149, Jackson Immu-
noresearch) was used as the secondary for the recombi-
nant antibodies. Proteins were detected with ECL
reagents (#RPN2106V1 and #RPN2106V2, GE Health
care).
Immunoprecipitation
HC2 (EGFRvIII transfected)a n dA 4 3 1( E G F Rw tt r a n s -
fected) cell lysates were isolated as described in the wes-
tern blot section and 300 μl of lysate was incubated
with 12 μg of G100 antibody (formerly commercially
available from Zymed lab, now discontinued), RAb
CD133
and RAb
DMvIII for 1 hr at 4°C. Forty μls of washed 50%
slurry of protein Gammabind G Sepharose (17-0885-01,
GE Healthcare) was added to each lysate/antibody mix
and incubated overnight at 4C. Immunoprecipitates
were washed three times with the same lysis buffer and
resuspended in sample buffer containing b-mercap-
toethanol. Immunocomplexes were resolved on 4-20%
Tris-glycine SDS-PAGE gels under normal reducing
conditions and transferred to nitrocellulose membranes
for immunoblot analysis by mouse anti-EGFR antibody
(E3138, Sigma Aldrich).
Immunofluorescence
HC2 and A431 cells were fixed in 4% paraformaldehyde,
permeabilized with 0.5% Triton X, and blocked with 5%
goat serum (0060-01, Southern Biotech). The following
antibodies were used for IF: RAb
DMvIII,m o u s ea n t i -
EGFR (EGFR (528): sc-120, Santa Cruz Biotechnology).
FITC goat anti-human (A11013, Jackson Immunore-
search) and FITC goat anti-mouse (A11029, Jackson
Immunoresearch) were used as secondary antibodies.
Images were obtained using a Leica SP2 AOBS Confocal
Laser Scanning Microscope. For peptide competition,
~20 times higher molar concentration of EGFRvIII pep-
tide (LEEKKGNYVVTDH-C, Genscript) and scrambled
peptide (WELKVNGTKDEYH-C, Genscript) was incu-
bated with the primary antibody at 37°C for 1 hour and
the mixture was centrifuged at 14000 × g for 5 min.
The supernatant was used at the primary antibody incu-
bation step of immunofluorescence protocol.
Immunohistochemistry
Slides were deparaffinized in xylene, and rehydrated in
decreasing percentages of ethanol. 3% hydrogen perox-
ide was used to block endogenous peroxidase and the
slides were placed in Diva Decloaker (BioCare Medical)
a n dm i c r o w a v e df o r1 3m i n u t e s1 0s e c o n d sf o ra n t i g e n
retrieval. After a cooling down period, the slides were
treated with Sniper Universal serum (BioCare Medical)
and then incubated with the following antibodies at 0.5
μg/ml overnight at 4°C: Rabbit anti-EGFR antibody,
RAb
CD133 (recombinant negative control) and RAb
DMvIII.
Each slide was then incubated with the appropriate sec-
ondary and/or tertiary antibody. The secondary antibo-
dies used were: HRP-Anti Rabbit (BioCare Medical),
anti-Human IgG rabbit (I9135, Sigma), HRP anti-rabbit
antibody (BioCare Medical). Protein expression was
detected by betazoid DAB (BioCare Medical). The slides
were also counterstained with hematoxylin. Glioblas-
toma slides were analyzed in a similar fashion to the
A431 and U87-MGvIII slides except that the slides for
RAb
DMvIII were blocked with equal volume of back-
ground sniper (BioCare Medical), 5% Blotto and normal
human serum (31876, Fisher) and the secondary anti-
body for RAb
DMvIII was rabbit anti-V5 (A00623, Gen-
script) followed by the tertiary antibody, which was
HRP-anti-rabbit (BioCare medical).
Enzyme-Linked Immunosorbent Assay (ELISA)
To determine the affinity constant of the RAb
DMvIII a
preliminary ELISA was performed to find the concentra-
tion of the antibody. This preliminary ELISA was per-
formed with both RAb
DMvIII and RAb
vIII antibodies to
compare the dissociation constant of both the antibodies.
A dilution series of antibodies RAb
DMvIII and RAb
vIII
(20 μg/ml-0.01952 μg/ml) in 5% blotto was used. ELISA
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Page 10 of 13plates were first coated with 10 μg/ml of EGFRvIII pep-
tide in coating solution in duplicate for each antibody
overnight at 4C. The next day the plates were washed
with 1× wash buffer (50-63-00, KpL) and 5% blotto was
added for 1 hr at RT. Thereafter the respective plates
were incubated with different dilutions of RAb
DMvIII and
RAb
vIII ranging from 20 μg/ml to 0.02 μg/ml in 5% blotto
for 1 hr at RT. The plates were washed 3 × 10 min each
with 1× wash buffer, and then affinity pure Donkey anti-
Human IgG (709-035-149, Jackson Immunoresearch)
was applied at a 1: 5000 dilution in 5% Blotto for 1 hr at
RT, and then the plates were washed 3 × 10 min each.
100 μl of 1× developing reagent was added to each reac-
tion well, and after 10 min., 100 μlo fs t o ps o l u t i o n1 N
HCl was added and the absorbance was read at 450 nm.
All curves reached a maximum value, which indicated
that the reactions proceeded until saturation. The data
was plotted as the absorbance at 450 nm versus different
antibody concentrations. This gave an equilibrium disso-
ciation constant, Kd,f o rR A b
DMvIII of 886 nM and for
RAb
vIII of 1.7 μM.
Determination of Affinity Constant
Indirect ELISA was performed to determine the affinity
constant of the recombinant antibody. This method
developed by Friguet et al [33] uses a solid-phase assay
for measuring the amount of free antibody present at
equilibrium in an antigen-antibody reaction mixture.
Since the RAb
DMvIII has a lower dissociation constant
than RAb
vIII as shown by preliminary ELISA we decided
to perform indirect ELISA with RAb
DMvIII only.
Two ninety-six well ELISA plates (353279, BD Falcon)
were coated overnight at 4°C with EGFRvIII peptide
LEEKKGNYVVTDH-C at a decreasing concentration
from 40 ug/ml to 2.5 μg/ml in coating solution (50-84-
00, KpL). Wells were then blocked with 5% nonfat dry
milk for 1 hr at room temperature. In parallel tubes,
antibody at 234 nM is incubated with double the con-
centration of antigen used in the plates that is (80 μg/
ml-5 μg/ml) in equal volume for final concentration of
a n t i b o d yt ob e1 1 7n M( l e s st han the dissociation con-
stant of RAb
DMvIII ) and final antigen concentration of
(40 μg/ml-2.5 μg/ml) for 30 min at RT, and then the
antibody-antigen mixture is transferred to the wells of
the first antigen coated microtiter plate and incubated
for 15 min. After this incubation, the contents are then
transferred to the second antigen coated plate and incu-
bated for another 15 min. The plates were washed with
wash buffer (50-63-00, KpL) and secondary donkey anti-
Human antibody from Jackson ImmunoResearch was
added for 1 hr incubation at RT. After further washes of
3 × 10 min each, 100 μl of substrate (53-00-02, KpL) is
applied and 100 μl of stop solution (1 N HCl) is added
after 10 min. The absorbance was read at 450 nm in an
ELISA plate reader. The data is plotted as the fraction
of bound antibody sites versus the ratio of (fraction of
bound antibody/concentration of free antigen). The
slope gives the value of K, which is the affinity constant.
Flowcytometry
Flowcytometric analysis was performed using RAb
DMvIII
for native cell surface expressed EGFRvIII. U87-MGwt,
U87-MGvIII, A431, and HC2 cell lines were dissociated
using TryplE® (Invitrogen, Carlsbad, CA). Cells were
resuspended in flow cytometry buffer, consisting of 1×
HBSS, pH 7.2, containing 1.55 g/l glucose and 0.1% frac-
tion V of bovine serum albumin (BSA; Sigma-Aldrich,
St. Louis,). Cells were counted and diluted to a density
of 10
6 cells per milliliter of buffer. 1 μgo fR A b
DMvIII
was used per 10
6 cells unless otherwise specified. Cells
were analyzed on a BD LSR-I flowcytometer (BD Bios-
ciences). Unlabeled cells and cells labeled with isotype
control (human IgG1) were used to set gating para-
meters between positive and negative cell populations.
Cell aggregates and small debris were excluded from
analysis or isolation on the basis of side scatter (measur-
ing cell granularity) and forward scatter (measuring cell
size); dead cells were excluded from analysis on the
basis of viability dye fluorescence (propidium Iodide).
Fluorescent intensities for cells in the population were
point-plotted on two-axis graphs or histogram using
FlowJo software (Tree Star Inc.).
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